Description
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It is studied for its ability to stimulate growth hormone (GH) release without significantly affecting cortisol or prolactin, making it a targeted option in muscle, bone, and recovery research.
Benefits
- Growth hormone release — studied for increasing circulating GH with minimal side effects.
- Muscle support — explored for lean mass preservation and recovery.
- Bone strength — interest in supporting bone density in aging models.
- Fat metabolism — linked to improved body composition in research settings.
- Recovery and repair — investigated for enhancing tissue healing via GH pathways.
What researchers look at
- Mechanism: selective ghrelin receptor agonist that stimulates GH release.
- Minimal impact on ACTH, cortisol, or prolactin compared to other GHS compounds.
- Muscle and bone effects in preclinical and clinical studies.
- Potential synergy with GHRH analogs (e.g., CJC-1295) in GH axis research.
Quick Specs
- Form: Lyophilized peptide
- Net per vial: 10 mg
- Purity: ≥99% (HPLC)
- Identity: MS-verified (per COA)
- Storage: 2–8 °C, protect from light
Identity Basics
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Formula / M.W.: C38H49N9O5, ~711.9 g/mol
- CAS: 170851-70-4
Selected Research
- PubChem entry — chemical identity:
https://pubchem.ncbi.nlm.nih.gov/compound/16132392
- Selective GH release profile study (1998):
https://pubmed.ncbi.nlm.nih.gov/9691368/
- Comparison to other GHS compounds (2002):
https://pubmed.ncbi.nlm.nih.gov/12107229/
- GH axis synergy with GHRH analogs (2004):
https://pubmed.ncbi.nlm.nih.gov/15240392/
⚠️ Disclaimer
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
